Rochester Science

The Rochester Nomogram will revolutionize LASIK eye surgery

Imagine a world of blurry images and words, where contact lenses and glasses are the only way to see clearly. For some people, this world is a reality. But as of recently there is a solution to the problem that is FDA approved and has a success rate that is guaranteed for an individual’s eyesight to be perfect.

Scott MacRae, M.D. and Manoj Venkiteshwar, Ph.D., invented a complex formula to better improve LASIK surgery by helping physicians determine how refractive surgery will affect the patient’s eyesight. A U.S. patent has been recently issued for the technology to help thousands of people around the world boost their eyesight. The formula is called Rochester Nomogram.

For those of you who don’t have any background information on the subject, there are a few things you must know. The cornea is the part of the eye that helps focus light to create an image for you to see. It almost works just like the lens of a camera and how it focuses when a person takes a picture. What takes place in a LASIK surgery is the corneal tissue is removed by a special laser that reshapes the cornea to change the focus of the individual’s eyesight.

Nomogram adjusts the way the laser in the surgery interacts with the patient’s eye tissue without risking the patient’s eyesight. The formula also reduces the number of repeat surgeries that most patients must endure in order to perfect their eyesight and not rely on contact lenses or glasses.

Said MacRae at the European Society of Cataract and Refractive Surgeons meeting,

Eyesight is crucial to everyone’s quality of life. As a physician, I am required to do everything in my power to make sure each of my patients has the very best vision possible.

Tens of thousands of people around the world have had vision procedures that have been associated with Nomogram. As of now, 99.3 percent of MacRae’s patients are seeing 20/20 vision or better after their surgery.

“It’s also gratifying that our work is benefiting not only our own patients but also others around the world,” added MacRae.

Rochester Technology

Kodak says they have 20 interested patent buyers. Well, sorta.

While Brighton Securities and others seem less than thrilled with Kodak’s patent sale prospects, Kodak themselves have released a statement declaring that in fact 20 companies have signed confidentiality agreements to look into patent purchases:

Kodak Files Motion for Competitive Auction of Digital Imaging Patents

Over the past 12 months, Kodak’s financial advisor, Lazard, has conducted an extensive marketing process for these assets. To date, 20 parties have signed confidentiality agreements and have been provided access to an electronic data room.

This is a bit of parsing. Just because a company signs a confidentiality agreement with Kodak does not in any way imply that they’re actually going to buy anything. The confidentiality agreement just protects both parties’ company secrets so that the bidding company can feel free to have a look around.

The company is currently looking for approval of a confidential bidding system. Is this for the sake of potential buyers, or to save face when nobody bids?

Rochester Technology

Kodak says it will appeal ruling on Apple/RIM patents

In the sunniest terms possible, Kodak claims a partial victory in the Apple and RIM patent suit they had originally hoped would yield a billion-dollar payout.

The presser points out that, while the current ruling claims that Apple and RIM did violate the patent but that the patent is invalid, one previous ruling was exactly the opposite. They plan to appeal. What’s the chances that they go double-zippo in the next one?